WebAug 11, 2024 · Financial Results for the Six Months Ended June 30, 2024. Net loss for the six months ended June 30, 2024 was $18.4 million compared to $19.2 million for the same period in 2024. Research and development expense for the six months ended June 30, 2024 was $10.1 million compared to $10.6 million for the same period in 2024. WebJun 30, 2024 · Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2024, and Recent Corporate Developments REDWOOD CITY, Calif., …
Graybug Vision Reports Financial Results for the Three and Six …
WebMar 11, 2024 · GRAYBUG VISION, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. ... (4,318 ) (41 )% Facility costs, travel and other 3,290 2,016 1,274 63 % Consulting 1,079 1,332 (253 ) (19 )% Materials and supplies 1,001 ... Cash provided by investing activities of $10.8 million during the year ended … WebMar 20, 2024 · CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement. by Globe Newswire. ... CalciMedica completed the … hurricane ian 2022 volusia county
Is Graybug Vision, Inc. (GRAY) A Good Stock To Buy? - Yahoo!
WebMay 10, 2024 · First Quarter 2024 Financial Results. Net loss for the quarter ended March 31, 2024 was $10.1 million compared to $11.4 million for the same period in 2024. WebApr 25, 2016 · REDWOOD CITY, CA--(Marketwired - Apr 25, 2016) - Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially … WebDec 31, 2024 · Cash used in operating activities of $10.7 million during the six months ended June 30, 2024 was primarily attributable to our net loss of $18.4 million partially offset by non-cash stock-based compensation of $3.3 million, $2.2 million in acquired in-process research and development and a decrease of $1.8 million in our working capital. hurricane ian 2022 track map